- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NeoGenomics Inc (NEO)"NeoGenomics Inc stock price live, this page displays NASDAQ NEO stock exchange data. View the NEO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the NeoGenomics Inc real time stock price chart below.
What Is the NeoGenomics Inc Stock Price Today?
The NeoGenomics Inc stock price today is 18.17.
What Is the Stock Symbol for NeoGenomics Inc?
The stock symbol for NeoGenomics Inc is ""NEO.""
What Stock Exchange Does NeoGenomics Inc Trade On?
NeoGenomics Inc is listed and trades on the NASDAQ stock exchange.
Is NeoGenomics Inc a Good Stock to Buy?
Determining whether NeoGenomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NEO quote. (ISIN: US64049M2098)"
What Is the NeoGenomics Inc Stock Price Today?
The NeoGenomics Inc stock price today is 18.17.
What Is the Stock Symbol for NeoGenomics Inc?
The stock symbol for NeoGenomics Inc is ""NEO.""
What Stock Exchange Does NeoGenomics Inc Trade On?
NeoGenomics Inc is listed and trades on the NASDAQ stock exchange.
Is NeoGenomics Inc a Good Stock to Buy?
Determining whether NeoGenomics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NEO quote. (ISIN: US64049M2098)"
18.17
-0.26(-1.41%)
Closed
After Hours
17.89-0.28(-1.54%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.16
18.67
52 wk Range
12.77
21.22
NEO Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.1618.67
52 wk Range
12.7721.22
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NEO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
21.00
Upside
+15.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
- NeoGenomics general counsel sells $79,475 in stock
- Investing.com
- NeoGenomics general counsel sells $79,475 in stock
- Investing.com
NeoGenomics Inc Company Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics Inc SWOT Analysis
Strategic Crossroads | Neo Performance Materials navigates crucial developments in rare earths and metals, balancing recent partnerships with ongoing corporate initiatives |
European Expansion | Explore Neo's agreement with a Tier 1 European automotive supplier, potentially opening doors to lucrative markets and validating the company's capabilities |
Market Dynamics | Delve into Neo's position in the competitive advanced materials sector, examining its strengths and challenges in serving automotive and electronics industries |
Future Prospects | Analyst sets C$13.00 price target, highlighting Neo's potential amid strategic alternatives review and recent operational streamlining efforts |
NEO Full Pro Research
Institutional-Grade Stock Analysis
Understand how NEO earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
NeoGenomics Inc Earnings Call Summary for Q4/2024
- Revenue up 10% to $168M, clinical services +14%, adjusted EBITDA +305% to $13M; NGS revenue +26%, now 31% of clinical volume
- Planned launches: NEO PanTracer liquid biopsy, NEO AML Express rapid test in early 2025; NEO Helix digital platform to enhance customer experience
- $388M cash to retire $201M convertible notes due May 2025; exploring strategic acquisitions to enhance market reach and NGS capabilities
- Record test volume (+9%) and revenue per test (+5%); optimistic about community oncology growth despite industry challenges
- Q3 revenue mix: 58% direct client billing, 15% commercial, 13% governmental; confident in continued Average Unit Price growth
Last Updated: 2024/11/07, 09:54
Read Full TranscriptCompare NEO to Peers and Sector
Metrics to compare | NEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −30.0x | −3.6x | −0.6x | |
PEG Ratio | −1.47 | −0.04 | 0.00 | |
Price/Book | 2.6x | 0.8x | 2.6x | |
Price / LTM Sales | 3.6x | 1.2x | 3.2x | |
Upside (Analyst Target) | 8.5% | 57.0% | 40.6% | |
Fair Value Upside | Unlock | 25.1% | 7.1% | Unlock |
Analysts' Recommendations
10 Buy
3 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 20.91
(+15.07% Upside)
FAQ
What Is the NeoGenomics (NEO) Stock Price Today?
The NeoGenomics stock price today is 18.17
What Stock Exchange Does NeoGenomics Trade On?
NeoGenomics is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for NeoGenomics?
The stock symbol for NeoGenomics is "NEO."
What Is the NeoGenomics Market Cap?
As of today, NeoGenomics market cap is 2.35B.
What is NeoGenomics Earnings Per Share?
The NeoGenomics EPS is -0.615.
What Is the Next NeoGenomics Earnings Date?
NeoGenomics will release its next earnings report on 24 Feb 2025.
From a Technical Analysis Perspective, Is NEO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.